Changes in protein-protein interactions that occur in response to environmental cues are difficult to uncover and have been poorly characterized to date. Here we describe a yeast-based assay that allows many binary protein interactions to be assessed in parallel and under various conditions. This method combines molecular barcoding and tag array technology with the murine dihydrofolate reductase-based protein-fragment complementation assay. A total of 238 protein-fragment complementation assay strains, each representing a unique binary protein complex, were tagged with molecular barcodes, pooled, and then interrogated against a panel of 80 diverse small molecules. Our method successfully identified specific disruption of the Hom3:Fpr1 interaction by the immunosuppressant FK506, illustrating the assay's capacity to identify chemical inhibitors of protein-protein interactions. Among the additional findings was specific cellular depletion of the Dst1:Rbp9 complex by the anthracycline drug doxorubicin, but not by the related drug idarubicin. The assay also revealed chemical-induced accumulation of several binary multidrug transporter complexes that largely paralleled increases in transcript levels. Further assessment of two such interactions (Tpo1: Pdr5 and Snq2:Pdr5) in the presence of 1,246 unique chemical compounds revealed a positive correlation between drug lipophilicity and the drug response in yeast.
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protein network | cell-based assay | drug screening | chemogenomics P rotein-protein interactions (PPIs) are of fundamental importance to virtually all cellular processes, including signal transduction and regulation of gene expression. Emergent highthroughput technologies that identify protein complexes and/or binary interactions have produced a wealth of information and have further underscored the ubiquitous role that PPIs play in cell biology (1) (2) (3) (4) (5) (6) (7) (8) . Although changes in protein complexes can occur from routine biochemical signaling events (i.e., posttranslational modification, protein degradation, or relocalization), the aforementioned studies were performed under standard growth conditions, and thus network connectivity changes that occur in response to different environmental cues remain ill-defined. Measuring such changes-for example, in response to chemical (i.e., small molecule) perturbations-is valuable in understanding both cellular systems and the biological effects of the chemical in question (9) . The cell's "interactome" also represents a tremendous opportunity for unique therapeutic strategies. Small-molecule drugs that directly inhibit specific PPIs could be used to modulate the activity of certain cellular processes while minimally interfering with others. PPIs are perceived to be among the most challenging targets for small molecules because of the sheer size of the interaction interface and the lack of small, deep cavities amenable to small-molecule binding (reviewed in ref. 10). Thus, despite an ever-increasing commitment by drug developers to pursue PPIs, and a growing list of small molecules that can disrupt PPIs, a need exists for new approaches to identifying such inhibitors and better illuminating the druggability of this coveted class of therapeutic targets (11, 12) .
The protein-fragment complementation assay (PCA) is an established method for identifying interactions between protein pairs (13) . In this assay, two proteins of interest are fused to complementary fragments of a reporter protein, and, upon interaction of the two fusion proteins, the reporter is reconstituted. DNA barcodes, on the other hand, permit multiplexing of biological samples rather than laboriously assaying them one at a time. For example, the incorporation of unique 20mer DNA sequences in the yeast deletion mutant collections enables thousands of individual strains to be assayed simultaneously (14) (15) (16) . Here we combine the PCA methodology with molecular barcode technology in a multiplex assay to (i) identify chemical modulators of PPIs, (ii) better understand the dynamic nature of the PPI network, and (iii) characterize the mode of action of bioactive chemicals. We have tested the effects of 80 diverse compounds on a set of barcoded PCA strains representing 238 unique binary complexes. Our results validate this approach as an effective method for highly parallel analysis of dynamic PPIs in vivo.
Results
Construction of a Pool of BarCoded PCA Strains. In the murine dihydrofolate reductase-based protein-fragment complementation assay (mDHFR PCA), the interaction of two proteins of interest allows a yeast strain to grow in the presence of the DHFR inhibitor methotrexate (MTX). The assay is based on a mutated version of the murine DHFR enzyme that is insensitive to MTX but has full catalytic activity in yeast (17, 18) . This tool has been used to systematically interrogate nearly all possible binary combinations of yeast proteins and has led to the identification of 2,770 PPIs (8) . We randomly selected strains representing 384 PPIs from this dataset and tested their ability to grow in liquid media in the presence of MTX (Fig. 1) . Approximately 64% of the strains (246 to be exact) were verified to grow under our culture conditions. We also constructed a strain harboring the Hom3:Fpr1 protein pair, an interaction that was not reported in ref. 8 but that was identified in yeast two-hybrid screens (5, 6) . Importantly, the interaction between Hom3 and Fpr1 was previously shown to be disrupted by the immunosuppressive drug FK506 (tacrolimus) (19) . The Hom3:Fpr1 PCA strain exhibited robust growth under MTX selection, indicating that the PCA system successfully identifies an interaction between the two proteins.
The growth rates of these 247 PCA strains were virtually indistinguishable in the absence of MTX selection (Fig. 2A) ; however, a wide range of growth rates were observed when MTX was present in the media (Fig. 2B) . Although the precise underlying cause of these growth differences is not completely understood, differences in the absolute number of reconstituted mDHFR complexes per cell is presumably the major factor.
Two unique molecular barcodes (an "UP tag" and a "DOWN tag") were used to determine the abundance of individual strains following competitive (i.e., pooled) growth under MTX selection. Ten replicate pool experiments were performed to assess reproducibility (SI Materials and Methods). The raw fluorescence values of the UP tag and DOWN tag for each strain were found Author contributions: U.S., R.W.D., and R.P.S. designed research; U.S., M.M., and S.S. performed research; U.S. and R.P.S. analyzed data; and U.S. and R.P.S. wrote the paper.
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Data deposition: The microarray data reported in this paper has been deposited in the European Bioinformatics Institute's repository ArrayExpress, http://www.ebi.ac.uk/arrayexpress (accession no. E-MEXP-3467). 1 To whom correspondence should be addressed. E-mail: bstonge@stanford.edu. to be well correlated (R = 0.79; Fig. 2C ), the majority of barcodes (96%) were detected in all samples (Fig. 2D) , and a pair-wise comparison of the 10 replicates showed a very high correlation (R = 0.98; Fig. 2E ). We also observed a strong correlation between array hybridization signal following pooled growth and growth rate measured in isogenic cultures (R = 0.88; Fig. 2F ). Taken together, these data demonstrate that the growth kinetics of many individual PCA strains, and therefore their underlying protein complexes, can be interrogated in a single pooled culture with high reproducibility.
Multiplex Interrogation of Protein-Protein Interactions with Small
Molecules. When applied to the PCA pool, chemical compounds that alter the abundance of a specific binary complex will concurrently change the number of reconstituted mDHFR complexes per cell, which will alter the cell's resistance to MTX and thus change the growth rate of that strain relative to others in the pool. In principle, chemicals could elicit these changes directly by disrupting the interaction interface between proteins or indirectly, for example, by altering gene expression and consequently the abundance of either member of the protein complex. We tested the impact of 80 compounds (Dataset S1) on the 238 strains (those with tag signals above background) in our PCA pool. An interaction score was calculated for all chemical-PPI pairs on the basis of the change in barcode abundance, and thus on the basis of the change in the underlying binary complex, in response to chemical treatment (Dataset S2 and SI Materials and Methods). Twelve chemical-PPI pairs with interaction scores < −10 and 42 pairs with interaction scores >10 are highlighted in red and green, respectively (Fig. 3A) . These 54 pairs and 6 pairs with scores close to zero were retested using isogenic cultures (Dataset S3). Data from the pooled and the single-strain cultures were in good agreement (R = 0.88; Fig. 3B ), and from these data we assembled a high-confidence list of 46 chemical-induced changes (6 cases of reduced binary complex levels and 40 cases of increased levels) (SI Materials and Methods and Dataset S3).
Among the high-confidence chemical-PPI pairs was Hom3: Fpr1 in FK506. The Hom3:Fpr1 strain clearly exhibited the strongest sensitivity to FK506 compared with other strains in the pool (Fig. 3C ). FK506 treatment also resulted in a specific increase in growth of the Pdr5:Pdr5, Tpo1:Pdr5, and Snq2:Snq2 strains ( Fig. 3C and discussed further in Fig. 5 ). We further examined the effects of FK506 on growth of individual strains both in the presence and the absence of MTX (representative growth curves are shown in Fig. S1 ). Consistent with the multiplex assay, the Hom3:Fpr1 strain was highly sensitive to FK506 relative to a control strain when both were grown under MTX selection (Fig. 3D , Upper Right). Similarly, the Pdr5:Pdr5, Tpo1:Pdr5, and Snq2:Snq2 strains were confirmed to grow significantly faster in response to FK506 (Fig. 3D , Lower Right). Importantly, these strain-specific FK506-induced growth changes were entirely dependent on MTX selection and were not observed when strains were grown in the absence of MTX (Fig. 3D , Left panels). Collectively, these results are consistent with FK506-dependent reduction in the cellular abundance of the Hom3:Fpr1 complex and with increase in the Pdr5:Pdr5, Tpo1:Pdr5, and Snq2:Snq2 complexes. More broadly, given that FK506 is known to disrupt the Hom3:Fpr1 interaction directly (19) , our results indicate that mDHFR-PCA interactions are reversible in vivo and thus amenable to identifying chemical inhibitors of PPIs. In addition, they demonstrate that loss (or gain) of a single PPI can be readily detected with our multiplex assay.
Specific Depletion of the Dst1:Rbp9 Complex by Doxorubicin in Vivo.
We observed that growth of the Dst1:Rpb9 strain was specifically inhibited by the anthracycline drug doxorubicin in our multiplex assay (Fig. 4A ). Rpb9 is a subunit of RNA polymerase II, and Dst1 is a general transcription elongation factor for RNA polymerase II that enables elongation through transcription arrest sites (20, 21) . Doxorubicin (adriamycin) is used to treat cancer and is thought to work primarily by intercalating DNA and inhibiting the progression of topoisomerase II (22, 23) . In yeast, Ssl2, a DNA-dependent helicase, has been identified as a potential target of doxorubicin (24, 25) . As a member of the RNA polymerase transcription factor TFIIH complex, Ssl2 is thought to have dual roles in nucleotide excision repair and transcription (26, 27) . Thus, doxorubicin-dependent decrease of Dst1:Rpb9 complex levels further supports an emerging, yet enigmatic, mechanism for doxorubicin involving transcription. We explored this result further by testing the effects of doxorubicin and three related anthracycline drugs (daunorubicin, epirubicin, and idarubicin) on the Dst1:Rpb9 strain in isogenic cultures (Fig. 4B) . Under MTX selection, doxorubicin, daunorubicin, and epirubicin each decreased growth of the Dst1:Rpb9 strain relative to the control; however, idarubicin did not specifically inhibit this strain relative to the control (Fig. 4C) . Importantly, Dst1:Rpb9-specific chemical sensitivity was not observed in the absence of MTX selection (Fig. S2A) , suggesting that the observed growth changes are indeed the result of changes in cellular levels of the Dst1:Rpb9 complex.
Similar to their effects on Dst1:Rpb9, doxorubicin, daunorubicin, and epirubicin each induced haploinsufficiency of SSL2, whereas idarubicin did not (Fig. 4D) . These results identify the 4-methoxy group (which is absent in idarubicin) as critical for the effects on both the Dst1:Rpb9 complex and SSL2 haploinsufficiency. This structure-activity relationship is perhaps surprising given that all four drugs are DNA intercalators, as illustrated by the sensitivity of the rad55Δ and rad57Δ homozygous yeast deletion strains (Fig. 4E) .
Given their widespread and overlapping clinical applications, further investigation of these differences in yeast and humans is certainly warranted. We note that doxorubicin-dependent depletion of Dst1:Rpb9 cannot be explained by down-regulation of either gene (Fig. S2B ), but whether doxorubicin disrupts this interaction directly remains to be determined.
Specific Depletion of the Cit2:Cit2 Complex by Multiple Chemical
Compounds. The remaining four high-confidence chemical-PPI pairs in which a strain exhibited specific sensitivity in our pool assay, each involved the Cit2:Cit2 strain. This strain was found to be sensitive to four compounds when grown under MTX selection: haematommic acid ethyl ester, cbf_5236571, chaulmoogric acid, and methyl 7-deshydroxypyrogallin-4-carboxylate (Fig. S3A) . CIT2 encodes the peroxisomal citrate synthase that catalyzes the condensation of acetyl CoA and oxaloacetate to form citrate (28) . Reduced growth of the isogenic Cit2:Cit2 strain in response to each compound was verified to be dependent on MTX selection (Fig. S3 B and C) . Examination of CIT2 transcript levels revealed a significant decrease in response to each of these chemical compounds (Fig.  S3D) , suggesting that the observed reduction in the Cit2:Cit2 complex is perhaps best explained by reduced transcript levels and thus Cit2 abundance. The origin and potential benefits of this cellular adaptation to chemical stress remain unknown.
Chemical-Induced Accumulation of Multidrug Transporter Complexes.
Instances of chemical-induced growth increases identified by our screens overwhelmingly involved strains representing multidrug transporter complexes, specifically, Pdr5:Pdr5, Snq2:Snq2, and Tpo1:Pdr5 (Fig. 3A) . We examined whether these three strains responded differently to the 80 chemical compounds tested. Hierarchical clustering of the interaction scores for these three strains identified three distinct clusters of compounds (Fig. 5A and Fig. S4 ). The first cluster contained compounds that enhanced growth of all three strains, but especially the Pdr5:Pdr5 strain. Compounds in the second cluster weakly enhanced the three strains, but showed no preference for Pdr5:Pdr5. In contrast, the third cluster contained compounds that specifically enhanced growth of the Snq2:Snq2 strain. We verified the specificity for Snq2:Snq2 for one chemical in this cluster (cbf_5236571) using isogenic cultures (Fig. S5A ). These findings demonstrate that the cell's response to different chemical insults is complex and mediated through different ABC transporters, as noted previously (29) . It has been previously demonstrated that transcript levels of SNQ2 and PDR5 are induced several fold in response to FK506 (30) . Indeed, we observed that FK506-enhanced growth of the Tpo1:Pdr5 strain was dependent on Pdr1 (Fig. S5B) , a transcription factor that controls the expression of many multidrug resistance genes (31, 32) . We therefore reasoned that the accumulation of binary pump complexes could be due, at least in part, to transcriptional up-regulation of the corresponding genes. We confirmed this with quantitative RT-PCR and found a strong induction of PDR5 and a moderate activation of the SNQ2 and TPO1 genes in response to FK506 (Fig. 5B) . Similarly, transcript levels of SNQ2 were strongly induced following exposure to cbf_5236571, whereas expression of both PDR5 and TPO1 did not change greatly (Fig. 5B) .
To further explore the drug response in yeast, we used a simple growth assay to measure abundance changes of the Tpo1:Pdr5 and Snq2:Pdr5 binary complexes in response to 1,246 unique chemical compounds (Dataset S4). In total, 388 compounds (∼31% of those tested) strongly enhanced growth of the Tpo1:Pdr5 and/or the Snq2:Pdr5 strains. We examined this group of molecules (hereafter referred to as active compounds) for shared properties and found that nitrogen-containing compounds were significantly less likely to be among the active set (χ 2 -test, P = 8.09 * 10
−18
). We also found the lipophilicity (LogP) of actives to be significantly higher (mean LogP = 3.15) than the remaining compounds (mean LogP = 1.72) (P = 1.22 * 10 −22
; Fig. 5C ). These results expand previous work demonstrating induction of drug pumps by membrane-active compounds (33) . Active compounds also tended to have fewer hydrogen bond acceptors and donors compared with inactive compounds; however, the molecular weight of active and inactive compounds did not differ significantly (Fig. 5C) .
Discussion
In the present study, a robust cell-based assay was developed by applying molecular barcoding to the mDHFR PCA system and . Growth relative to that in the absence of drug is indicated by the y axis. The mean of four independent replicates is plotted. Error bars represent the SD. (D) Growth in rich media (yeast extract/peptone/dextrose broth) of the hoΔ/HO (control) and ssl2Δ/SSL2 heterozygous deletion strains in the presence of increasing concentrations of doxorubicin, daunorubicin, epirubicin, or idarubicin. Growth relative to that in the absence of drug is indicated by the y axis, and drug concentration on the x axis. The mean of three independent replicates is plotted. Error bars represent the SD. (E) As in D, but involving the hoΔ/hoΔ, rad55Δ/rad55Δ, and rad57Δ/rad57Δ homozygous deletion strains.
thus allowing parallel analysis of protein-protein complexes in their natural cellular environment. We applied this assay to measure changes (both positive and negative) in 238 binary protein complexes in response to 80 unique chemical entities. With few exceptions, these 80 chemicals were not preselected on the basis of biological activity in yeast; however, 14 inhibited growth of a wildtype strain in the absence of MTX selection (Dataset S1). In total, 22 of the 80 chemicals that we tested induced a change in at least one binary complex, the majority of which involved drug-efflux pumps (Fig. 3A) . Poor cell permeability can be an obstacle of cellbased assays in yeast, whose cell wall and elaborate chemical defense mechanisms represent a formidable barrier to many chemical compounds. Although it is unclear how many compounds were actually able to penetrate into yeast, prescreening compounds for growth inhibition of a wild-type strain, applying computational models to prioritize cell-permeable bioactive compounds (34), or genetically disabling yeast's chemical defense mechanisms (35, 36) could each increase the number of compounds effectively entering the cell in future studies. Indeed, in the current study our "hit rate" was much higher for growth inhibitory compounds, as 13 of the 14 growth inhibitors identified at least one change in our multiplex assay. Our approach readily identified the previously described disruption of Hom3:Fpr1 by FK506 (19) (Fig. 3 C and D) . This observation confirms that the mDHFR-based PCA system is reversible. Even though this had been aptly demonstrated in vitro (8) , it was important to verify in vivo, given the irreversibility of other, specifically, popular fluorescent proteinbased PCAs (37) . This result also demonstrates that disruption of a single PPI can be easily detected in a pool of strains representing hundreds of unique PPIs.
Among the chemical-dependent changes that we identified was the reduced abundance of the Dst1:Rpb9 complex in the presence of doxorubicin, a founding member of the anthracycline class of chemotherapeutic drugs (38) . Despite their longstanding and widespread clinical use, the therapeutic mechanism of action of anthracyclines remains ill-defined. Inhibition of topoisomerase II is often regarded as the basis of anthracyclines' potent anti-tumor effects; however, experimental evidence supports other mechanisms as well (39) . Recent work has identified Ssl2 as the likely target of doxorubicin in yeast that is rate-limiting for growth (24, 25) . Doxorubicin's effect on Dst1:Rpb9 (Fig. 4 A and C) is especially noteworthy, given the functional relationship between Ssl2 (a component of the RNA polymerase transcription factor TFIIH) and these two proteins: Dst1 is a transcription elongation factor for RNA Pol II and Rpb9 is a subunit of RNA Pol II required for transcription start-site selection (20, 21, 40, 41) . These functional links, in addition to the similar structure-activity relationships that we observed (Fig. 4  B-D) , strongly suggest that SSL2 haploinsufficiency and cellular depletion of the Dst1:Rpb9 complex are interdependent somehow. Our results point to a mechanism for doxorubicinmediated growth inhibition that may involve transcription startsite selection, transcript elongation through arrest sites, or both.
Multidrug resistance continues to be a major obstacle in effectively treating many cancers (42) . The utility of yeast as a model for studying multidrug resistance is supported by its vast repertoire of drug transporters (29, 35) and by the homology of both Pdr5 and Snq2 to human Mdr1, a major contributor to tumor resistance (43, 44) . Of the 80 chemicals screened in this study, 21 (26.25%) yielded an interaction score >10 in at least one of three drug-pump strains (Pdr5:Pdr5, Snq2:Snq2, or Tpo1: Pdr5). We took advantage of this phenomenon to assess the yeast drug response in ∼1,250 unique chemical compounds using a simple growth assay. The observation that elevated chemical lipophilicity significantly correlates with accumulation of binary pump complexes confirms on a broad level earlier studies that were based on a small number of chemicals (33) . Extending these assays to larger numbers of small molecules could lead to a better understanding of the chemical features that trigger the multidrug response in yeast or even to predictive models that could aid in designing more effective therapeutics. The highly multiplexed nature of our assay allows for the interrogation of many binary protein complexes in a single experiment. The pool of ∼250 strains described here can easily be increased in complexity to interrogate more PPIs. Furthermore, this approach is not limited to yeast proteins, but can also be adapted for studying interactions between proteins from higher eukaryotes (1-4). Our current results suggest that additional screens involving more complex pools will reveal the dynamic nature of the cell's interactome, provide valuable mechanistic information for bioactive compounds, and extend our understanding of PPI druggability.
Materials and Methods
Media and Growth Conditions. PCA-PPI harboring strains were selected in minimal media supplemented with 100 μg/mL MTX. Isogenic cultures (100 μL) were inoculated at a concentration of 0.01 OD 600 /mL and grown in 96-well microtiter plates at 30°C. Optical density was measured every 15 min over the course of several hours (as indicated in graphs) using a GENios microplate reader (Tecan). Area under the curve (AUC) was used to assess growth, a detailed description of which is in SI Materials and Methods.
PCA Pool Construction and Screening. The Yeast Interactome Collection (YSC5849) from Open Biosystems was used to construct a pool of barcoded mDHFR-tagged strains (described in SI Materials and Methods). Frozen aliquots of the pool were recovered in minimal media and then diluted in minimal media plus MTX. Cells were then grown in the presence of chemical compound or DMSO in 700-μL cultures in a 48-well microplate. The screening concentrations of all compounds tested are listed in Dataset S1. After five generations of growth, cells were harvested, and genomic DNA was extracted. PCR amplification of barcodes and hybridization to Genflex Tag 16k arrays (Affymetrix) were performed as described previously (45) . Raw data are available via EBI's ArrayExpress archive (accession no. E-MEXP-3467). Data analysis and the calculation of "interaction scores" for each chemical-PPI pair are described in SI Materials and Methods.
Quantitative RT-PCR Experiments. Total RNA was extracted from strain BY4743 growing in minimal media in the presence of compound or DMSO (control) using the RiboPure-Yeast kit (Ambion). RNA was reverse-transcribed into cDNA using SuperScript II (Invitrogen) and oligo(dT)12-18 primer (Invitrogen). Data analysis and the calculation of fold changes of transcript levels in response to drug treatment are described in SI Materials and Methods.
